Literature DB >> 12833520

Analysis of complex autoantibody repertoires by surface-enhanced laser desorption/ionization-time of flight mass spectrometry.

Franz H Grus1, S C Joachim, Norbert Pfeiffer.   

Abstract

Normal sera contain a large number of naturally occurring autoantibodies which can mask important disease-associated ones. Western blotting has evolved as the most important tool to demonstrate autoantibodies in autoimmune diseases, because of its ability to simultaneous screening for a wide spectrum of different antigens. In previous studies we have shown the diagnostic potential of the analysis of autoantibodies in autoimmune diseases by means of multivariate statistics and artificial neural networks. However, the Western blotting procedure remains very time-consuming and is also limited in sensitivity. Therefore, we used an on-chip approach for the analysis of autoantibodies. This ProteinChip system uses ProteinChip arrays and SELDI-TOF MS (surface-enhanced laser desorption/ionization-time of flight mass spectrometry) technology for capturing, detection, and analysis of proteins without labelling or without the need of chemical modification. The microscale design of the arrays allows the analysis of very small quantities of proteins. In the present study, we used arrays with biologically activated surfaces that permit antibody capture studies. Protein-A-Chips were incubated with sera of patients (n = 12). After washing, the chips were incubated with a complex solution of autoantigens and subsequently washed again. If the Protein-A bound autoantibodies recognized their antigens, these proteins could be separated by their molecular masses and were to be detected by mass spectrometry. Previous studies using monoclonal antibodies have demonstrated that the detection limit is in the attomole level. Furthermore, all sera were analyzed by conventional Western blotting for direct comparison. In the present study, we have shown complex on-chip antibody-antigen reactions. At higher molecular weights (> 30 kDa) the detection sensitivity of this on-chip method was comparable to conventional Western blotting. At lower molecular mass, the Western blot technique is easily exceeded by the on-chip method. Considering that this on-chip procedure is quite easy to use, is much less time-consuming than Western blotting, and is much more sensitive at least in the low molecular weight range, the SELDI-TOF technology is a very promising approach for the screening of autoantibodies in autoimmune diseases. Due to its versatility, this on-chip technology could allow the large-scale screening for complex autoantibody distributions for diagnostic purposes and early detection of autoimmune diseases might be possible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12833520     DOI: 10.1002/pmic.200300375

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  5 in total

1.  Molecular biomarkers in glaucoma.

Authors:  Sanjoy K Bhattacharya; Richard K Lee; Franz H Grus
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-07       Impact factor: 4.799

Review 2.  Glaucoma: recent advances in the involvement of autoimmunity.

Authors:  Maria Ida Rizzo; Antonio Greco; Armando De Virgilio; Andrea Gallo; Luciano Taverniti; Massimo Fusconi; Michela Conte; Giulio Pagliuca; Rosaria Turchetta; Marco de Vincentiis
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 3.  Immunological mechanisms in glaucoma.

Authors:  F Grus; D Sun
Journal:  Semin Immunopathol       Date:  2008-03-11       Impact factor: 9.623

4.  Synthetic Polyclonal-Derived CDR Peptides as an Innovative Strategy in Glaucoma Therapy.

Authors:  Carsten Schmelter; Kristian Nzogang Fomo; Natarajan Perumal; Caroline Manicam; Katharina Bell; Norbert Pfeiffer; Franz H Grus
Journal:  J Clin Med       Date:  2019-08-15       Impact factor: 4.241

Review 5.  What does the future hold for clinical microbiology?

Authors:  Didier Raoult; Pierre Edouard Fournier; Michel Drancourt
Journal:  Nat Rev Microbiol       Date:  2004-02       Impact factor: 60.633

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.